West Pharmaceutical Services, Inc. (WST) is a prominent global healthcare company based in Exton, Pennsylvania. The company specializes in designing, manufacturing, and selling innovative containment and delivery systems for injectable drugs and healthcare products. With a market cap of approximately $19.2 billion, West Pharmaceutical is a leader in the industry.
As a large-cap stock valued at over $10 billion, West Pharmaceutical stands out as a top manufacturer of packaging components and delivery systems for injectable drugs. Despite experiencing a 23.6% decline from its 52-week high of $348.90 in January, the company has witnessed a 3.1% increase in shares over the past three months. However, this growth lags behind the 12.5% gains of the Health Care Select Sector SPDR Fund (XLV) during the same period.
On a year-to-date basis, West Pharmaceutical has underperformed, with an 18.7% decline compared to XLV’s 12% gains. Over the past 52 weeks, the company’s shares have dipped by 19.4%, while XLV has seen a 10.6% increase during the same period. Despite these challenges, West Pharmaceutical has been trading above the 50-day moving average since early June and the 200-day moving average since mid-September.
Investor concerns about the company’s outlook and operational challenges have contributed to its decline in 2025. Pricing headwinds, tariff-related cost pressures, and inventory destocking by customers have impacted near-term growth prospects. In comparison, rival company Thermo Fisher Scientific Inc. (TMO) has outperformed West Pharmaceutical, with a 7.8% gain over the past 52 weeks and a 9.6% increase year-to-date.
Despite its underperformance, West Pharmaceutical has a consensus rating of “Strong Buy” from 17 analysts, with a mean price target of $345.36 suggesting a potential upside of 29.6%. It is important to note that the information and data provided in this article are for informational purposes only. The original article was published on Barchart.com.
In conclusion, West Pharmaceutical Services, Inc. continues to be a key player in the healthcare industry, despite facing challenges in the market. With a focus on innovation and a strong position in the injectable drug delivery systems sector, the company remains poised for growth in the long term.
